Bio-Rad Laboratories (BIO) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $585.4M, down 4.2% year-over-year, with Clinical Diagnostics slightly outperforming forecasts and Life Science segment facing softness, especially in academia and biopharma research.

• Gross margin declined to 52.3% from 53.4% year-over-year; non-GAAP gross margin was 53.8%.

• Net income was $64.0M ($2.29 per diluted share), down from $383.9M ($13.45) in Q1 2024, mainly due to lower gains from equity securities.

• Operating cash flow increased to $129.9M from $69.8M year-over-year, driven by lower cash paid to suppliers and employees.

• Management approved a new restructuring plan in February 2025, incurring $35.5M in related expenses in Q1.

Financial highlights

• Life Science segment sales fell 5.4% to $228.6M; Clinical Diagnostics sales decreased 3.2% to $356.8M year-over-year; currency-neutral total sales declined 1.5%.

• Q1 GAAP gross margin was 52.3%; non-GAAP gross margin was 53.8%.

• Q1 operating income was $24M (4% of sales), down from $45M (7.3% of sales) year-over-year; non-GAAP operating income was $63M.

• Q1 non-GAAP net income was $71M ($2.54 per diluted share).

• Free cash flow for Q1 was $96M, up from $30M in Q1 2024; cash and short-term investments at quarter-end were $1.66B.

Outlook and guidance

• 2025 currency-neutral revenue expected to range from a 1% decline to 1.5% growth, 225 basis points lower than prior guidance.

• Life Science business now expected to be flat to down 3% for the year; Clinical Diagnostics growth outlook reduced by 100 basis points to 0.5%–2.5%.

• Full-year non-GAAP gross margin projected at 53%–54.5% (down from 55%–55.5% prior), with the reduction attributed to tariffs.

• Non-GAAP operating margin forecasted at 10%–12%; non-GAAP tax rate expected at 22%.

• Management expects continued uncertainty in global economic and geopolitical conditions, with reduced government spending and biopharma market challenges likely to persist through 2025.